Robert Lütjens

Biography

  Dr. Lütjens, who joined Addex at its founding in 2002, is an accomplished preclinical drug developer and expert in allosteric modulation with more than 20 years experience. At Addex, Dr Lütjens was responsible for establishing the Addex small molecule allosteric modulator biology platform. He led the high through put screening campaigns which successfully discovered the Addex clinical and preclinical pipeline of first in class small molecule allosteric modulators. He has played a pivotal role in the development of Addex portfolio which delivered several molecules into the clinic, including dipraglurant for PD-LID. In addition, Dr. Lütjens managed numerous research collaborations both with academic and industrial partners, and in particular with Janssen Pharmaceuticals Inc., which has led to the successful progression of the first mGluR2 positive allosteric modulator into man. Prior to joining Addex, he completed a postdoctoral fellowship in the Department of Neuropharmacology at the Scripps Research Institute, in La Jolla, CA, where he focused on understanding molecular changes involved in addiction disorders. Dr Lütjens obtained his degrees in Biology from the University of Geneva, his master’s at the Swiss Institute for Experimental Cancer Research and his Ph.D. thesis at the Glaxo Institute for Molecular Biology in Geneva and the Institute for Cellular Biology and Morphology in Lausanne. Dr. Lütjens is co-author of over 25 peer-reviewed publications and co-inventor on patents covering screening methods or chemical compounds.  

Research Interest

 Biology